ERBB2 and breast carcinoma: When comparing the clinico‐pathological characteristics of patients with TNBC, HR+ and HER2+ breast cancer, we observed, as expected,31, 32 a higher proportion of lymph node metastasis at diagnosis in patients with HR+ and HER2+ tumors compared to patients with TNBC (p < 0.05).